Novel Pan-Coronavirus 3CL Protease Inhibitor MK-7845: Biological and Pharmacological Profiling

Novel Pan-Coronavirus 3CL Protease Inhibitor MK-7845: Biological and Pharmacological Profiling

Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) continues to be a global threat due to its ability to evolve and generate new subvariants, leading to new waves of infection. Additionally, other coronaviruses like Middle East respiratory syndrome coronavirus (MERS-CoV, formerly know...

Full description

Bibliographic Details
Main Authors: Nadine Alvarez, Gregory C. Adam, John A. Howe, Vijeta Sharma, Matthew D. Zimmerman, Enriko Dolgov, Risha Rasheed, Fatima Nizar, Khushboo Sahay, Andrew M. Nelson, Steven Park, Xiaoyan Zhou, Christine Burlein, John F. Fay, Daniel V. Iwamoto, Carolyn M. Bahnck-Teets, Krista L. Getty, Shih Lin Goh, Imad Salhab, Keith Smith, Christopher W. Boyce, Tamara D. Cabalu, Nicholas Murgolo, Nicholas G. Fox, Todd W. Mayhood, Valerie W. Shurtleff, Mark E. Layton, Craig A. Parish, John A. McCauley, David B. Olsen, David S. Perlin
Format: Article
Language:English
Published: MDPI AG 2024-07-01
Series:Viruses
Subjects:
coronavirus
SARS-CoV-2
MERS-CoV
3CLPro
antivirals
protease inhibitors
Online Access:https://www.mdpi.com/1999-4915/16/7/1158

Internet

https://www.mdpi.com/1999-4915/16/7/1158

Similar Items